ClinicalTrials.Veeva

Menu

Effect of Flax in Yogurt on Blood Cyanide Levels

S

St. Boniface Hospital

Status

Not yet enrolling

Conditions

Healthy

Treatments

Dietary Supplement: 40 g roasted then ground whole flaxseed
Dietary Supplement: 40 g of whole intact flaxseeds
Dietary Supplement: 0 g Flax
Dietary Supplement: 28 g flax hulls
Dietary Supplement: 40 g whole ground flaxseed

Study type

Interventional

Funder types

Other

Identifiers

NCT06491095
4030/4687

Details and patient eligibility

About

A randomized, controlled, cross-over post-prandial trial in healthy human volunteers will be conducted at the IH Asper Institute to determine the effect whole ground flaxseed, roasted then ground whole flaxseed, whole intact flaxseed and flaxseed hulls mixed into yogurt on blood cyanide levels.

Full description

Participants will receive yogurt containing the following flaxseed products in a random order:

  1. 40 g ground flaxseed, untreated;
  2. 40 g ground flaxseed, roasted before grinding;
  3. 40 g intact whole flaxseed;
  4. 28 g flaxseed hulls;
  5. 0 g flaxseed.

Venous blood will be collected at the following time points: 0 (before consumption of test product), 15, 30, 45, 60, 75, 90, 120, 150, 180 min.

Urine will be collected prior to consumption of test product and 180 min.

Primary endpoints: 1) Peak blood level of cyanide and incremental area under the curve (iAUC) for cyanide in blood over a 3h postprandial period. Secondary endpoint: 1) cyanogenic glycoside and thiocyanate concentrations in plasma and urine over a 3h postprandial period.

Tertiary endpoints: 1) metabolic profile in plasma and urine over 3 h postprandial period.

Enrollment

12 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Generally healthy adult, 18 years or older;
  2. Willing to provide informed consent;
  3. Willing/able to comply with the requirements of the study.

Exclusion criteria

  1. Pregnant or lactating;
  2. Medical history of disease that is currently under treatment;
  3. Active treatment for any type of cancer within 1 year prior to study start;
  4. Presence of a gastrointestinal disorder, daily use of any stomach acid-lowering medications or laxatives (including fibre supplements) within the past month or antibiotic use within the past 6 weeks;
  5. Plasma concentration of vitamin B12 < 148 pmol/L;
  6. Complete blood count outside normal range;
  7. Medical history of liver disease or liver dysfunction (defined as plasma AST or ALT ≥3 times the upper limit of normal (ULN));
  8. Fasting blood glucose ≥6.1 mmol/L and/or HbA1c ≥6.0%;
  9. Fasting plasma total cholesterol >7.8 mmol/L;
  10. Fasting plasma HDL <0.9 mmol/L;
  11. Fasting plasma LDL >5.0 mmol/L;
  12. Fasting plasma triglycerides >2.3 mmol/L;
  13. Systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg;
  14. Major surgery within the last 3 months;
  15. Smoking, use of tobacco, vape or cannabis (within the last week);
  16. Allergies to flaxseed or yogurt;
  17. Aversion or unwillingness to eat study foods;
  18. Participation in another clinical trial, current or in the past 4 weeks

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

12 participants in 5 patient groups

No Flax Product
Other group
Description:
175 g yogurt containing no flax product
Treatment:
Dietary Supplement: 0 g Flax
40 g whole ground flaxseed
Experimental group
Description:
175 g yogurt with 40 g whole ground flaxseed
Treatment:
Dietary Supplement: 40 g whole ground flaxseed
40 g roasted then ground whole flaxseed
Experimental group
Description:
175 g yogurt with 40 g roasted then ground whole flaxseed
Treatment:
Dietary Supplement: 40 g roasted then ground whole flaxseed
40 g of whole intact flaxseeds
Experimental group
Description:
175 g yogurt with 40 g of whole intact flaxseeds
Treatment:
Dietary Supplement: 40 g of whole intact flaxseeds
28 g flax hulls
Experimental group
Description:
175 g yogurt with 28 g flax hulls
Treatment:
Dietary Supplement: 28 g flax hulls

Trial contacts and locations

1

Loading...

Central trial contact

Heather Blewett, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems